<DOC>
	<DOC>NCT00273494</DOC>
	<brief_summary>Hypothesis is that surgery is of benefit in locally advanced NSCLC with N2 disease. Patients are randomised to surgery or not.</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2</brief_title>
	<detailed_description>Patients are after staging randomised to neoadj. chemotherapy followed by surgery followed by irradiation or to chemotherapy followed by irradiation. Endpoint is survival.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically verified NSCLC Stage IIIA/N2 age 1875 Lung function test allowing surgery Mediastinoscopy performed Prior chemotherapy Prior irradiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>N2 disease</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Surgery</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
</DOC>